You are here

  • Home
  • Archive
  • Volume 95, Issue 9
  • T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Citation Tools

Article menu
Multiple sclerosis
Original research
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Verstegen NJM, Hagen RR, Kreher C on behalf of T2B! immunity against SARS-CoV-2 study group, et al
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Journal of Neurology, Neurosurgery & Psychiatry 2024;95:855-864.